

By: Representatives Willis, Paden, Reynolds

To: Drug Policy

HOUSE BILL NO. 1547

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,  
2 TO REVISE SCHEDULE I OF THE CONTROLLED SUBSTANCES ACT TO INCLUDE  
3 CERTAIN SYNTHETIC CANNABINOIDS, FENTANYLS AND FENTANYL-LIKE  
4 SUBSTANCES THAT HAVE NO ACCEPTED MEDICAL USE; TO AMEND SECTION  
5 41-29-115, MISSISSIPPI CODE OF 1972, TO AMEND SCHEDULE II TO  
6 EXCLUDE NALDEMEDINE; TO AMEND SECTION 41-29-121, MISSISSIPPI CODE  
7 OF 1972, TO REVISE SCHEDULE V TO INCLUDE A CANNABINOID THAT HAS  
8 BEEN APPROVED AS A LEGEND DRUG BY THE FEDERAL FOOD AND DRUG  
9 ADMINISTRATION; AND FOR RELATED PURPOSES.

10 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

11 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is  
12 amended as follows:

13 41-29-113. \* \* \*

14 **SCHEDULE I**

15 (a) Schedule I consists of the drugs and other substances,  
16 by whatever official name, common or usual name, chemical name, or  
17 brand name designated, that is listed in this section.

18 ( \* \* \*b) **Opiates.** Unless specifically excepted or unless  
19 listed in another schedule, any of the following opiates,  
20 including their isomers, esters, ethers, salts and salts of  
21 isomers, esters and ethers, \* \* \* whenever the existence of these



22 isomers, esters, ethers and salts is possible within the specific  
23 chemical designation:

24 (1) Acetyl-alpha-methylfentanyl;

25 (2) Acetyl Fentanyl

26 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;

27 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
28 cyclohexylmethyl]benzamide);

29 (4) Acetylmethadol;

30 (5) Allylprodine;

31 (6) Alphacetylmethadol, except levo-alphacetylmethadol  
32 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

33 (7) Alphameprodine;

34 (8) Alphamethadol;

35 (9) Alpha-methylfentanyl;

36 (10) Alpha-methylthiofentanyl;

37 (11) Benzethidine;

38 (12) Betacetylmethadol;

39 (13) Beta-hydroxyfentanyl;

40 (14) Beta-hydroxy-3-methylfentanyl;

41 (15) Betameprodine;

42 (16) Betamethadol;

43 (17) Betaprodine;

44 (18) Butyrl fentanyl

45 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

46 (19) Clonitazene;



47 ( \* \* \*20) Dextromoramide;

48 ( \* \* \*21) Diampromide;

49 ( \* \* \*22) Diethylthiambutene;

50 ( \* \* \*23) Difenoquin;

51 ( \* \* \*24) Dimenoxadol;

52 ( \* \* \*25) Dimepseptanol;

53 ( \* \* \*26) Dimethylthiambutene;

54 ( \* \* \*27) Dioxaphetyl butyrate;

55 ( \* \* \*28) Dipipanone;

56 ( \* \* \*29) Ethylmethylthiambutene;

57 ( \* \* \*30) Etonitazene;

58 ( \* \* \*31) Etoxadidine;

59 ( \* \* \*32) Fentanyl-related substances, meaning any

60 substance not otherwise listed under another schedule and for

61 which no exemption or approval is in effect under Section 505 of

62 the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is

63 structurally related to fentanyl by one or more of the following

64 modifications:

65 (A) Replacement of the phenyl portion of the

66 phenethyl group by any monocycle, whether or not further

67 substituted in or on the monocycle;

68 (B) Substitution in or on the phenethyl group with

69 alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino or nitro

70 groups;



71 (C) Substitution in or on the piperidine ring with  
72 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,  
73 amino or nitro groups;

74 (D) Replacement of the aniline ring with any  
75 aromatic monocycle whether or not further substituted in or on the  
76 aromatic monocycle; and/or

77 (E) Replacement of the N-propionyl group by  
78 another acyl group.

79 Fentanyl-related substances include, but are not limited to,  
80 cyclopropyl fentanyl,

81 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

82 Furanyl-Fentanyl,

83 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

84 valeryl fentanyl,

85 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);

86 para-fluorobutyryl fentanyl,

87 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

88 para-methoxybutyryl fentanyl,

89 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

90 para-chloroisobutyryl fentanyl,

91 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

92 isobutyryl fentanyl,

93 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);



94 cyclopentyl fentanyl,  
95 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);  
96 and  
97 ocfentanil,  
98 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami  
99 de);

- 100 ( \* \* \*33) Furethidine;  
101 ( \* \* \*34) Hydroxypethidine;  
102 ( \* \* \*35) Ketobemidone (including the optical and  
103 geometric isomers);  
104 ( \* \* \*36) Levomoramide;  
105 ( \* \* \*37) Levophenacylmorphane;  
106 ( \* \* \*38) 3-methylfentanyl;  
107 ( \* \* \*39) 3-methylthiofentanyl;  
108 ( \* \* \*40) Morpheridine;  
109 ( \* \* \*41) MPPP  
110 (1-methyl-4-phenyl-4-propionoxypiperidine);

111 \* \* \*

112 (42)

113 *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylprop  
114 ionamide, its isomers, esters, ethers, salts and salts of isomers,  
115 esters and ethers (other names: beta-hydroxythiofentanyl);

116 (43) Noracymethadol;

117 (44) Norlevorphanol;

118 (45) Normethadone;



- 119 (46) Norpipanone;  
120 (47) Para-fluorofentanyl;  
121 (48) PEPAP  
122 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
123 (49) Phenadoxone;  
124 (50) Phenampromide;  
125 (51) Phenomorphan;  
126 (52) Phenoperidine;  
127 (53) Piritramide;  
128 (54) Proheptazine;  
129 (55) Properidine;  
130 (56) Propiram;  
131 (57) Racemoramide;  
132 (58) Thiofentanyl;  
133 (59) Tilidine;  
134 (60) Trimeperidine;  
135 (61) U-47700,

136 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

137 ( \* \* \*c) **Opium derivatives.** Unless specifically excepted  
138 or unless listed in another schedule, any of the following opium  
139 derivatives, their salts, isomers and salts of isomers, \* \* \*  
140 whenever the existence of these salts, isomers and salts of  
141 isomers is possible within the specific chemical designation:

- 142 (1) Acetorphine;  
143 (2) Acetyldihydrocodeine;



- 144 (3) Benzylmorphine;  
145 (4) Codeine methylbromide;  
146 (5) Codeine-N-Oxide;  
147 (6) Cyprenorphine;  
148 (7) Desomorphine;  
149 (8) Dihydromorphine;  
150 (9) Drotebanol;  
151 (10) Etorphine (except hydrochloride salt);  
152 (11) Heroin;  
153 (12) Hydromorphinol;  
154 (13) Methyldesorphine;  
155 (14) Methyldihydromorphine;  
156 (15) Monoacetylmorphine;  
157 (16) Morphine methylbromide;  
158 (17) Morphine methylsulfonate;  
159 (18) Morphine-N-Oxide;  
160 (19) Myrophine;  
161 (20) Nicocodeine;  
162 (21) Nicomorphine;  
163 (22) Normorphine;  
164 (23) Pholcodine;  
165 (24) Thebacon.

166 ( \* \* \*d) **Hallucinogenic substances.** Unless specifically  
167 excepted or unless listed in another schedule, any material,  
168 compound, mixture or preparation which contains any quantity of



169 the following substances, their salts, isomers (whether optical,  
170 positional, or geometric) and salts of isomers, \* \* \* whenever the  
171 existence of these salts, isomers and salts of isomers is possible  
172 within the specific chemical designation:

- 173 (1) Alpha-ethyltryptamine;
- 174 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 175 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 176 (4) 2,5-dimethoxyamphetamine;
- 177 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 178 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine  
179 (2C-T-7);
- 180 (7) 4-methoxyamphetamine;
- 181 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 182 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 183 (10) 3,4-methylenedioxy amphetamine;
- 184 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 185 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known  
186 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl  
187 MDA, MDE, MDEA);
- 188 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also  
189 known as N-hydroxy MDA, N-OHMDA, and  
190 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 191 (14) 3,4,5-trimethoxy amphetamine;
- 192 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 193 (16) Alpha-methyltryptamine (also known as AMT);





- 194 (17) Bufotenine;
- 195 (18) Diethyltryptamine;
- 196 (19) Dimethyltryptamine;
- 197 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 198 (21) Ibogaine;
- 199 (22) Lysergic acid diethylamide (LSD);
- 200 (23) (A) Marijuana (Cannabidiol contained in a legend  
201 drug product approved by the Federal Food and Drug Administration  
202 or obtained under Section 41-29-136 is exempt under Schedule I);
- 203 (B) Hashish;
- 204 (24) Mescaline;
- 205 (25) Parahexyl;
- 206 (26) Peyote;
- 207 (27) N-ethyl-3-piperidyl benzilate;
- 208 (28) N-methyl-3-piperidyl benzilate;
- 209 (29) Psilocybin;
- 210 (30) Psilocyn;
- 211 (31) Tetrahydrocannabinols, meaning  
212 tetrahydrocannabinols contained in a plant of the genus Cannabis  
213 (cannabis plant), as well as the synthetic equivalents of the  
214 substances contained in the cannabis plant, or in the resinous  
215 extractives of such plant, and/or synthetic substances,  
216 derivatives, and their isomers with similar chemical structure and  
217 pharmacological activity to those substances contained in the  
218 plant such as the following:



- 219 (A) 1 cis or trans tetrahydrocannabinol;  
220 (B) 6 cis or trans tetrahydrocannabinol;  
221 (C) 3,4 cis or trans tetrahydrocannabinol.

222 (Since nomenclature of these substances is not  
223 internationally standardized, compounds of these structures,  
224 regardless of atomic positions, are covered.)

225 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

226 However, the following products are exempted from control:

227 (i) THC-containing industrial products made  
228 from cannabis stalks (e.g., paper, rope and clothing);

229 (ii) Processed cannabis plant materials used  
230 for industrial purposes, such as fiber retted from cannabis stalks  
231 for use in manufacturing textiles or rope;

232 (iii) Animal feed mixtures that contain  
233 sterilized cannabis seeds and other ingredients (not derived from  
234 the cannabis plant) in a formula designed, marketed and  
235 distributed for nonhuman consumption;

236 (iv) Personal care products that contain oil  
237 from sterilized cannabis seeds, such as shampoos, soaps, and body  
238 lotions (if the products do not cause THC to enter the human  
239 body); and

240 (v) Processed cannabis plant extract, oil or  
241 resin with a minimum ratio of twenty-to-one cannabidiol to  
242 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and  
243 diluted so as to contain at least fifty (50) milligrams of



244 cannabidiol per milliliter, with not more than two and one-half  
245 (2.5) milligrams of tetrahydrocannabinol per milliliter;  
246 (32) Phencyclidine;  
247 (33) Ethylamine analog of phencyclidine (PCE);  
248 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);  
249 (35) Thiophene analog of phencyclidine;  
250 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);  
251 (37) 4-methylmethcathinone (mephedrone);  
252 (38) 3,4-methylenedioxypropylvalerone (MDPV);  
253 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);  
254 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);  
255 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);  
256 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);  
257 or 2,5-dimethoxy-4-iodophenethylamine;  
258 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine  
259 (2C-T-2);  
260 (44)  
261 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);  
262 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);  
263 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);  
264 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine  
265 (2C-P);  
266 (48) 3,4-methylenedioxy-N-methylcathinone (methylone);



267 (49)  
268 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
269 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);  
270 (50)  
271 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine  
272 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);  
273 (51)  
274 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or  
275 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;  
276 Cimbi-5);  
277 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,  
278 4-benzodiazepin-2-one (also known as Phenazepam);  
279 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,  
280 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene  
281 (also known as Etizolam);  
282 (54) Salvia divinorum;  
283 (55) Synthetic cannabinoids. Unless specifically  
284 excepted or unless listed in another schedule, any material,  
285 compound, mixture, or preparation which contains any quantity of a  
286 synthetic cannabinoid found in any of the following chemical  
287 groups, whether or not substituted to any extent, or any of those  
288 groups which contain any synthetic cannabinoid salts, isomers, or  
289 salts of isomers, whenever the existence of such salts, isomers,  
290 or salts of isomers is possible within the specific chemical



291 designation, including all synthetic cannabinoid chemical  
292 analogues in such groups:

293 (A) (6aR,10aR)-9-(hydroxymethyl)-6,  
294 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]  
295 chromen-1-ol (also known as HU-210 or  
296 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

297 (B) Naphthoylindoles and naphthylmethylinindoles,  
298 being any compound structurally derived from 3-(1-naphthoyl)indole  
299 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted  
300 in the indole ring to any extent, or in the naphthyl ring to any  
301 extent;

302 (C) Naphthoylpyrroles, being any compound  
303 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not  
304 substituted in the pyrrole ring to any extent, or in the naphthyl  
305 ring to any extent;

306 (D) Naphthylmethylinindenes, being any compound  
307 structurally derived from 1-(1-naphthylmethyl)indene, whether or  
308 not substituted in the indene ring to any extent or in the  
309 naphthyl ring to any extent;

310 (E) Phenylacetylindoles, being any compound  
311 structurally derived from 3-phenylacetylindole, whether or not  
312 substituted in the indole ring to any extent or in the phenyl ring  
313 to any extent;

314 (F) Cyclohexylphenols, being any compound  
315 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether



316 or not substituted in the cyclohexyl ring to any extent or in the  
317 phenolic ring to any extent;

318 (G) Benzoylindoles, whether or not substituted in  
319 the indole ring to any extent or in the phenyl ring to any extent;

320 (H) Adamantoylindoles, whether or not substituted  
321 in the indole ring to any extent or in the adamantoyl ring system  
322 to any extent;

323 (I) Tetrahydro derivatives of cannabinal and  
324 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,  
325 except where contained in cannabis or cannabis resin;

326 (J) 3-Cyclopropylmethanone indole or  
327 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by  
328 substitution at the nitrogen atom of the indole ring, whether or  
329 not further substituted in the indole ring to any extent, whether  
330 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl  
331 rings to any extent;

332 (K) Quinoliny ester indoles, being any compound  
333 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny  
334 ester, whether or not substituted in the indole ring to any extent  
335 or the quinolone ring to any extent;

336 (L) 3-carboxamide-1H-indazoles, whether or not  
337 substituted in the indazole ring to any extent and substituted to  
338 any degree on the carboxamide nitrogen and  
339 3-carboxamide-1H-indoles, whether or not substituted in the indole



340 ring to any extent and substituted to any degree on the  
341 carboxamide nitrogen;

342 (M) Cycloalkanemethanone Indoles, whether or not  
343 substituted at the nitrogen atom on the indole ring, whether or  
344 not further substituted in the indole ring to any extent, whether  
345 or not substituted on the cycloalkane ring to any extent.

346 ( \* \* \*e) **Depressants.** Unless specifically excepted or  
347 unless listed in another schedule, any material, compound,  
348 mixture, or preparation which contains any quantity of the  
349 following substances having a depressant effect on the central  
350 nervous system, including their salts, isomers, and salts of  
351 isomers, whenever the existence of such salts, isomers, and salts  
352 of isomers is possible within the specific chemical designation:

353 (1) Gamma-hydroxybutyric acid (other names include:  
354 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic  
355 acid; sodium oxybate; sodium oxybutyrate);

356 (2) Mecloqualone;

357 (3) Methaqualone.

358 ( \* \* \*f) **Stimulants.** Any material, compound, mixture or  
359 preparation which contains any quantity of the following central  
360 nervous system stimulants including optical salts, isomers and  
361 salts of isomers unless specifically excepted or unless listed in  
362 another schedule:

363 (1) Aminorex;



- 364 (2) N-benzylpiperazine (also known as BZP \* \* \* and  
365 1-benzylpiperazine);
- 366 (3) Cathinone;
- 367 (4) Fenethylamine;
- 368 (5) Methcathinone;
- 369 (6) 4-methylaminorex (also known as  
370 2-amino-4-methyl-5-phenyl-2-oxazoline);
- 371 (7) N-ethylamphetamine;
- 372 (8) Any material, compound, mixture or preparation  
373 which contains any quantity of N,N-dimethylamphetamine. (Other  
374 names include: N,N,-alpha-trimethyl-benzeneethanamine \* \* \* and  
375 N,N-alpha-trimethylphenethylamine);
- 376 (9) **Synthetic cathinones.** (A) Unless listed in  
377 another schedule, any compound other than bupropion that is  
378 structurally derived from 2-Amino-1-phenyl-1-propanone by  
379 modification in any of the following ways:
- 380 (i) By substitution in the phenyl ring to any  
381 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide  
382 substituents, whether or not further substituted in the phenyl  
383 ring by one or more other univalent substituents;
- 384 (ii) By substitution at the 3-position with  
385 an alkyl substituent;
- 386 (iii) By substitution at the nitrogen atom  
387 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom  
388 in a cyclic structure.





389 (B) The compounds covered in this paragraph (9)  
390 include, but are not limited to, any material compound, mixture or  
391 preparation which contains any quantity of a synthetic cathinone  
392 found in any of the following compounds, whether or not  
393 substituted to any extent, or any of these compounds which contain  
394 any synthetic cathinone, or salts, isomers, or salts of isomers,  
395 whenever the existence of such salts, isomers or salts of isomers  
396 is possible, unless specifically excepted or listed in another  
397 schedule:

- 398 (i) 4-methyl-N-ethylcathinone ("4-MEC");  
399 (ii) 4-methyl-alpha-pyrrolidinopropiophenone  
400 ("4-MePPP");  
401 (iii) Alpha-pyrrolidinopentiophenone  
402 ("α-PVP");  
403 (iv)  
404 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");  
405 (v) 2-(methylamino)-1-phenylpentan-1-one  
406 ("pentedrone");  
407 (vi)  
408 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one  
409 ("pentylone");  
410 (vii) 4-fluoro-N-methylcathinone ("4-FMC");  
411 (viii) 3-fluoro-N-methylcathinone ("3-FMC");



412 (ix)  
413 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one  
414 ("naphyrone"); \* \* \*  
415 (x) Alpha-pyrrolidinobutiophenone  
416 (" $\alpha$ -PBP") \* \* \* ; and  
417 (xi)  
418 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one  
419 (N-ethylpentylone, ephylone).

420 **SECTION 2.** Section 41-29-115, Mississippi Code of 1972, is  
421 amended as follows:

422 41-29-115. ( \* \* \*a) The controlled substances listed in  
423 this section, by whatever official name, common or usual name,  
424 chemical name, or brand name designated, are included in Schedule  
425 II.

#### 426 **SCHEDULE II**

427 ( \* \* \*b) **Substances, vegetable origin or chemical**  
428 **synthesis.** Unless specifically excepted or unless listed in other  
429 schedules, any of the following substances, except those narcotic  
430 drugs listed in other schedules, whether produced directly or  
431 indirectly by extraction from substances of vegetable origin, or  
432 independently by means of chemical synthesis, or by combination of  
433 extraction and chemical synthesis:

434 (1) Opium and opiate, and any salt, compound,  
435 derivative, or preparation of opium or opiate, excluding  
436 apomorphine, thebaine-derived butorphanol, dextrorphan,



437 nalbuphine, naldemedine, nalmeffene, naloxegol, naloxone and  
438 naltrexone, but including the following:

- 439 (i) Codeine;
- 440 (ii) Dihydroetorphine;
- 441 (iii) Ethylmorphine;
- 442 (iv) Etorphine hydrochloride;
- 443 (v) Granulated opium;
- 444 (vi) Hydrocodone, whether alone or in combination  
445 with any material, compound, mixture or preparation;
- 446 (vii) Hydromorphone;
- 447 (viii) Metopon;
- 448 (ix) Morphine;
- 449 (x) Opium extracts;
- 450 (xi) Opium fluid extracts;
- 451 (xii) Oripavine;
- 452 (xiii) Oxycodone;
- 453 (xiv) Oxymorphone;
- 454 (xv) Powdered opium;
- 455 (xvi) Raw opium;
- 456 (xvii) Thebaine;
- 457 (xviii) Tincture of opium \* \* \*;

458 (2) Any salt, compound, isomer, derivative, or  
459 preparation thereof which is chemically equivalent or identical  
460 with any of the substances referred to in paragraph (1), but not  
461 including the isoquinoline alkaloids of opium;



462 (3) Opium poppy and poppy straw;  
463 (4) Coca leaves and any salt, compound, derivative, or  
464 preparation of cocaine or coca leaves, including cocaine and  
465 ecgonine and any salt, compound, derivative, isomer, or  
466 preparation thereof which is chemically equivalent or identical  
467 with any of these substances, but not including:

468 (i) Decocainized coca leaves or extraction of coca  
469 leaves, which extractions do not contain cocaine or ecgonine; or

470 (ii) Ioflupane;

471 (5) Concentrate of poppy straw (the crude extract of  
472 poppy straw in either liquid, solid or powder form which contains  
473 the phenanthrene alkaloids of the opium poppy).

474 ( \* \* \*c) **Opiates.** Any of the following opiates, including  
475 their isomers, esters, ethers, salts, and salts of isomers,  
476 whenever the existence of these isomers, esters, ethers and salts  
477 is possible within the specified chemical designation, dextrorphan  
478 and levopropoxyphene excepted:

479 (1) Alfentanil;

480 (2) Alphaprodine;

481 (3) Anileridine;

482 (4) Bezitramide;

483 (5) Bulk dextropropoxyphene (nondosage forms);

484 (6) Carfentanil;

485 (7) Dihydrocodeine;

486 (8) Diphenoxylate;



487 (9) Fentanyl;  
488 (10) Isomethadone;  
489 (11) Levo-alpha-acetylmethadol  
490 (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM);  
491 (12) Levomethorphan;  
492 (13) Levorphanol;  
493 (14) Metazocine;  
494 (15) Methadone;  
495 (16) Methadone-intermediate,  
496 4-cyano-2-dimethylamino-4,4-diphenyl butane;  
497 (17) Moramide-intermediate,  
498 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;  
499 (18) Pethidine (meperidine);  
500 (19) Pethidine-Intermediate-A,  
501 4-cyano-1-methyl-4-phenylpiperidine;  
502 (20) Pethidine-Intermediate-B,  
503 ethyl-4-phenylpiperidine-4-carboxylate;  
504 (21) Pethidine-Intermediate-C,  
505 1-methyl-4-phenylpiperidine-4-carboxylic acid;  
506 (22) Phenazocine;  
507 (23) Piminodine;  
508 (24) Racemethorphan;  
509 (25) Racemorphan;  
510 (26) Remifentanil;  
511 (27) Sufentanil;



512 (28) Tapentadol;  
513 (29) Thiafentanil,  
514 4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl  
515 ]piperidine.

516 ( \* \* \*d) **Stimulants.** Any material, compound, mixture, or  
517 preparation which contains any quantity of the following  
518 substances:

519 (1) Amphetamine, its salts, optical isomers, and salts  
520 of its optical isomers;

521 (2) Phenmetrazine and its salts;

522 (3) Any substance which contains any quantity of  
523 methamphetamine, including its salts, isomers, and salts of  
524 isomers;

525 (4) Methylphenidate and its salts;

526 (5) Lisdexamfetamine, its salts, isomers and salts of  
527 isomers.

528 ( \* \* \*e) **Depressants.** Unless specifically exempted or  
529 unless listed in another schedule, any material, compound,  
530 mixture, or preparation which contains any quantity of the  
531 following substances:

532 (1) Amobarbital;

533 (2) Secobarbital;

534 (3) Pentobarbital;

535 (4) Glutethimide.

536 ( \* \* \*f) **Hallucinogenic substances.**



537 (1) Dronabinol oral solution  
538 [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)];  
539 (2) Nabilone [other names include:  
540 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-  
541 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

542 ( \* \* \*g) **Immediate precursors.** Unless specifically  
543 excepted or unless listed in another schedule, any material,  
544 compound, mixture, or preparation which contains any quantity of  
545 the following substances:

546 (1) Amphetamine and methamphetamine immediate  
547 precursor: Phenylacetone (other names include:  
548 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl  
549 ketone);

550 (2) Phencyclidine immediate precursors:  
551 (i) 1-phenylcyclohexylamine;  
552 (ii) 1-piperidinocyclohexanecarbonitrile (PCC);

553 (3) Fentanyl immediate precursor:  
554 4-anilino-N-phenethyl-4-piperidine (ANPP).

555 ( \* \* \*h) Any material, compound, mixture or preparation  
556 which contains any quantity of a Schedule II controlled substance  
557 and is listed as an exempt substance in 21 CFR, Section 1308.24 or  
558 1308.32, shall be exempted from the provisions of the Uniform  
559 Controlled Substances Law.

560 **SECTION 3.** Section 41-29-121, Mississippi Code of 1972, is  
561 amended as follows:



562 41-29-121. \* \* \*

563 **SCHEDULE V**

564 (a) Schedule V consists of the drugs and other substances,  
565 by whatever official name, common or usual name, chemical name, or  
566 brand name designated, listed in this section.

567 (b) Narcotic drugs. [Reserved]

568 ( \* \* \*c) **Narcotic drugs containing nonnarcotic active**  
569 **medicinal ingredients.** Any compound, mixture or preparation  
570 containing \* \* \* any of the following narcotic drugs, or their  
571 salts calculated as the free anhydrous base or alkaloid, in  
572 limited quantities as set forth below, which also contains one or  
573 more nonnarcotic active medicinal ingredients in sufficient  
574 proportion to confer upon the compound, mixture or  
575 preparation \* \* \* valuable \* \* \* medicinal qualities other than  
576 those possessed by the narcotic drug alone:

577 (1) Not more than two hundred (200) milligrams of  
578 codeine, or any of its salts, per one hundred (100) milliliters or  
579 per one hundred (100) grams;

580 (2) Not more than one hundred (100) milligrams of  
581 dihydrocodeine, or any of its salts, per one hundred (100)  
582 milliliters or per one hundred (100) grams;

583 (3) Not more than one hundred (100) milligrams of  
584 ethylmorphine, or any of its salts, per one hundred (100)  
585 milliliters or per one hundred (100) grams;





586 (4) Not more than two and five-tenths (2.5) milligrams  
587 of diphenoxylate and not less than twenty-five (25) micrograms of  
588 atropine sulphate per dosage unit;

589 (5) Not more than one hundred (100) milligrams of opium  
590 per one hundred (100) milliliters or per one hundred (100) grams;

591 (6) Not more than five-tenths (0.5) milligram of  
592 difenoxin and not less than twenty-five (25) micrograms of  
593 atropine sulfate per dosage unit.

594 ( \* \* \*d) **Stimulants.** Unless specifically excepted or  
595 listed in another schedule, any material, compound, mixture or  
596 preparation which contains any quantity of the following  
597 substance, including its salts, isomers and salts of isomers:  
598 Pyrovalerone.

599 ( \* \* \*e) **Depressants.** Unless specifically exempted or  
600 excluded or unless listed in another schedule, any material,  
601 compound, mixture or preparation which contains any quantity of  
602 the following substances having a depressant effect on the central  
603 nervous system, including their salts, isomers and salts of  
604 isomers:

605 (1) Brivaracetam  
606 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also  
607 referred to as BRV; UCB-34714; Briviact);

608 (2) Ezogabine [N-[2-amino-4-(4-  
609 fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];



610 (3) Lacosamide  
611 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];  
612 (4) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
613 acid].  
614 (f) Approved cannabidiol drugs. A drug product in finished  
615 dosage formulation that has been approved by the United States  
616 Food and Drug Administration that contains cannabidiol  
617 (2-R-3-methyl-6R-1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-  
618 benzenediol) derived from cannabis and no more than 0.1 percent  
619 (w/w) residual tetrahydrocannabinols.

620 ( \* \* \*g) Any material, compound, mixture or preparation  
621 which contains any quantity of a Schedule V controlled substance  
622 and is listed as an exempt substance in 21 CFR, Section 1308.22,  
623 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the  
624 provisions of the Uniform Controlled Substances Law.

625 **SECTION 4.** This act shall take effect and be in force from  
626 and after its passage.

